,27–31 Data from DESTINY trials demonstrate that HER2 overexpression (IHC3+) remains the strongest predictor of response, while ERBB2 mutations show variable sensitivity and may inform future tumor-agnostic indications.24 Here, ERBB2 is linked to neoplasm.